[The effects of 3,4-dihydroxyacetophynone on the activity of nitric oxide synthetase in placental vascular endothelial cells and smooth muscle cells and on the level of endothelin-1 in plasma from pregnancy-induced hypertension patients]

What Was Tested

The paper reports a study of Endothelin-1, published as a randomized controlled trial.

To observe the effects of 3,4-dihydroxyacetophynone (DHAP), one of the constituents of a traditional Chinese herbal medicine, on the activities of endothelial nitric oxide synthetase (NOS) in vascular endothelial cells (VEC) and vascular smooth muscle cells (VSMC) of placenta and the level of endothelin-1 (ET-1) in the plasma from PIH patients.

Who Took Part

The abstract describes 22 patients taking part.

PubMed indexes the participants as adults, women only.

22 nulliparous PIH patients were randomly divided into PIH group and DHAP treatment group.

The placenta were assayed for nitric oxide synthase activity using histochemical analysis; the concentration of ET in plasma was measured by radioimmunoassays. 10 normal pregnant women or 10 nonpregnant women were served as controls.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Endothelin-1 and who got the comparison, which limits bias.

Blood samples were collected before the administration of DHAP and (or) before cesarean section.

What Was Measured

PubMed files the paper under topics including Acetophenones, Endothelin-1, Muscle, Smooth, Vascular, Nitric Oxide Synthase, Placenta, Platelet Aggregation Inhibitors and Pre-Eclampsia.

What This Means in Plain Language

The paper is a randomized study of Endothelin-1 in 22 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1996 (Zhonghua fu chan ke za zhi), a journal based in China.

More context: the Endothelin-1 compound page, all human trials.